{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-23-000002","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2023-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.131533+00:00","generated_at":"2026-06-20T20:56:08.976655+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moderna details 2023 strategic priorities; RSV trial nearly enrolled, flu vaccine accelerated pathway","bullets":["RSV vaccine Phase 3 enrolled >36,000 of 37,000 target; flu vaccine efficacy trial initiated in Northern Hemisphere.","Personalized cancer vaccine (mRNA-4157/V940) + KEYTRUDA cut recurrence or death risk by 44% in Phase 2 melanoma study.","First inhaled mRNA candidate (Vxc-522 for cystic fibrosis) cleared by FDA; relaxin Phase 1B dosed for heart failure.","Rare disease programs show promise: propionic acidemia MDE reductions; sixth candidate (OTC deficiency) added.","2023 priorities include building respiratory franchise, aggressive cancer vaccine program, and potential flu vaccine approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-23-000002","json":"https://secwatch.observer/filing/0001682852-23-000002.json","markdown":"https://secwatch.observer/filing/0001682852-23-000002.md","text":"https://secwatch.observer/filing/0001682852-23-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000002/0001682852-23-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285223000002/mrna-20230103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:56:08.976655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}